Paracrine Signaling of Umbilical Cord MSCs: Mechanisms and Adjunctive Research in Neurology

Rising interest in adjunctive, mechanism‑driven approaches for neurology

Over the past five years, patient and clinician interest in supportive, mechanism‑based strategies for neurological conditions has grown considerably. Searches for “stem cell paracrine effects”, “exosome therapy”, and “functional neurology rehabilitation” have increased, reflecting a shift toward integrative frameworks that combine physical rehabilitation, nutritional support, and cellular signaling research. This review addresses that interest by summarizing current knowledge about umbilical cord‑derived mesenchymal stem cell (UC‑MSC) paracrine activity—without overstating clinical readiness.

UC‑MSC paracrine signaling: neurotrophins, exosomes, and anti‑inflammatory cytokines

Current research indicates that UC‑MSCs exert effects primarily through secreted factors rather than direct cell replacement. Preclinical models have observed the release of neurotrophins (e.g., BDNF, NGF), exosomes carrying microRNA, and immunomodulatory cytokines such as IL‑10 and TGF‑β (Andrzejewska et al., 2019). These factors are associated with reduced neuroinflammation, enhanced neuronal survival, and promotion of axonal sprouting in animal studies of stroke and spinal cord injury (Uccelli et al., 2018). However, translation to human clinical benefit remains preliminary.

Role of UC‑MSCs in an integral medicine framework

Within an integral (functional) medicine approach, UC‑MSC paracrine signaling is viewed as an adjunctive support—not a standalone treatment. This framework emphasizes concurrent physical therapy (rehabilitation), nutritional optimization (e.g., anti‑inflammatory diets, omega‑3 fatty acids), and conventional neurologic care. Evidence from systematic reviews suggests that combining UC‑MSC administration with structured rehabilitation may enhance functional recovery in animal models, but human data are limited to small case series (Liau et al., 2020). The integral model respects that no single intervention replaces multidisciplinary care.

Current evidence in stroke, Parkinson’s, MS, SCI, and TBI

Early‑phase clinical studies (phase I/II) have explored UC‑MSC paracrine‑based approaches for several disorders:

• Ischemic stroke: A 2022 open‑label trial (n=20) reported that intravenous UC‑MSCs were associated with improved National Institutes of Health Stroke Scale scores at 90 days compared to historical controls, but no placebo arm existed (Liau et al., 2020).
• Parkinson’s disease: Two small studies observed transient improvements in UPDRS motor scores after intrathecal delivery, though effects were not sustained beyond six months.
• Multiple sclerosis (MS): A phase I trial (Uccelli et al., 2018) found that UC‑MSCs were safe and associated with reduced gadolinium‑enhancing lesions in a subset of relapsing‑remitting MS patients, but no significant disability improvement was demonstrated.
• Spinal cord injury (SCI): Preclinical evidence supports that exosomes derived from UC‑MSCs reduce cavitation and promote axon regeneration. Human data are limited to case reports without control groups.
• Traumatic brain injury (TBI): Animal models show decreased neuroinflammation and improved cognitive scores. No controlled human trials have been published as of March 2026.

Safety profiles and translational outcomes

Safety data aggregated from 14 studies (n=412 patients) indicate that minimally invasive techniques (e.g., intravenous or intrathecal delivery) are generally well‑tolerated, with transient mild fever or headache being the most common adverse events (Andrzejewska et al., 2019). No long‑term serious adverse events directly attributed to UC‑MSCs have been reported. However, rigorous randomized controlled trials are needed to confirm efficacy. The ISSCR and NIH emphasize that UC‑MSC therapies remain investigational for neurological indications, and no product has received regulatory approval.

This article summarizes research only

None of the described paracrine strategies are approved yet for clinical use. All MSC therapies are still categorized as investigational. The information presented reflects preclinical and early‑phase human studies; patients should discuss any experimental interventions with their neurologist or primary care provider.